155 related articles for article (PubMed ID: 38066512)
1. Combined utility of Ki-67 index and tumor grade to stratify patients with pancreatic ductal adenocarcinoma who underwent upfront surgery.
Li B; Yin X; Ding X; Zhang G; Jiang H; Chen C; Guo S; Jin G
BMC Surg; 2023 Dec; 23(1):370. PubMed ID: 38066512
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of Ki-67 proliferative index in resectable pancreatic ductal adenocarcinoma.
Pergolini I; Crippa S; Pagnanelli M; Belfiori G; Pucci A; Partelli S; Rubini C; Castelli P; Zamboni G; Falconi M
BJS Open; 2019 Oct; 3(5):646-655. PubMed ID: 31592095
[TBL] [Abstract][Full Text] [Related]
3. Negative p53 Expression Confers Worse Prognosis in Patients With Resected Pancreatic Ductal Adenocarcinoma: Research Focused on Reinterpretation of Immunohistochemical Staining.
Li B; Wang Y; Wang J; Zhang G; Yin X; Wang H; Jiang H; Jin G; Guo S
Pancreas; 2022 Oct; 51(9):1217-1224. PubMed ID: 37078948
[TBL] [Abstract][Full Text] [Related]
4. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
5. Comparison of 4- and 4 plus-courses S-1 administration as adjuvant chemotherapy for pancreatic ductal adenocarcinoma.
Li B; Shen S; You S; Zhang G; Gao S; Shi X; Wang H; Yin X; Xu X; Guo S; Jin G
BMC Cancer; 2021 May; 21(1):612. PubMed ID: 34034684
[TBL] [Abstract][Full Text] [Related]
6. Poorly differentiated resectable pancreatic cancer: is upfront resection worthwhile?
Crippa S; Partelli S; Zamboni G; Barugola G; Capelli P; Inama M; Bassi C; Pederzoli P; Falconi M
Surgery; 2012 Sep; 152(3 Suppl 1):S112-9. PubMed ID: 22766365
[TBL] [Abstract][Full Text] [Related]
7. Pros and Cons: High Proportion of Stromal Component Indicates Better Prognosis in Patients With Pancreatic Ductal Adenocarcinoma-A Research Based on the Evaluation of Whole-Mount Histological Slides.
Li B; Wang Y; Jiang H; Li B; Shi X; Gao S; Ni C; Zhang Z; Guo S; Xu J; Jin G
Front Oncol; 2020; 10():1472. PubMed ID: 32974173
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of preoperative prognostic factors in patients with resectable pancreatic ductal adenocarcinoma.
Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Shiihara M; Yamamoto M
Scand J Gastroenterol; 2019 Jun; 54(6):780-786. PubMed ID: 31180790
[No Abstract] [Full Text] [Related]
9. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
[TBL] [Abstract][Full Text] [Related]
10. Preoperative CT predictors of survival in patients with pancreatic ductal adenocarcinoma undergoing curative intent surgery.
Dickinson SM; McIntyre CA; Schilsky JB; Harrington KA; Gerst SR; Flynn JR; Gonen M; Capanu M; Wong W; Lawrence S; Allen PJ; O'Reilly EM; Jarnagin WR; D'Angelica MI; Balachandran VP; Drebin JA; Kingham TP; Simpson AL; Do RK
Abdom Radiol (NY); 2021 Apr; 46(4):1607-1617. PubMed ID: 32986175
[TBL] [Abstract][Full Text] [Related]
11. Estimating Recurrence after Upfront Surgery in Patients with Resectable Pancreatic Ductal Adenocarcinoma by Using Pancreatic CT: Development and Validation of a Risk Score.
Kim DW; Lee SS; Kim SO; Kim JH; Kim HJ; Byun JH; Yoo C; Kim KP; Song KB; Kim SC
Radiology; 2020 Sep; 296(3):541-551. PubMed ID: 32662759
[TBL] [Abstract][Full Text] [Related]
12. Refined prognostic staging for resected pancreatic cancer by modified stage grouping and addition of tumour grade.
König AK; Gros H; Hinz U; Hank T; Kaiser J; Hackert T; Bergmann F; Büchler MW; Strobel O
Eur J Surg Oncol; 2022 Jan; 48(1):113-120. PubMed ID: 34344573
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
14. Robotic pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: Analysis of surgical outcomes and long-term prognosis in a high-volume center.
Zhang XP; Xu S; Zhao ZM; Liu Q; Zhao GD; Hu MG; Tan XL; Liu R
Hepatobiliary Pancreat Dis Int; 2023 Apr; 22(2):140-146. PubMed ID: 36171169
[TBL] [Abstract][Full Text] [Related]
15. Duodenal Involvement is an Independent Prognostic Factor for Patients with Surgically Resected Pancreatic Ductal Adenocarcinoma.
Dal Molin M; Blackford AL; Siddiqui A; Brant A; Cho C; Rezaee N; Yu J; He J; Weiss M; Hruban RH; Wolfgang C; Goggins M
Ann Surg Oncol; 2017 Aug; 24(8):2379-2386. PubMed ID: 28439733
[TBL] [Abstract][Full Text] [Related]
16. A prospective comparison of the prognostic value of tumor- and patient-related factors in patients undergoing potentially curative surgery for pancreatic ductal adenocarcinoma.
Jamieson NB; Denley SM; Logue J; MacKenzie DJ; Foulis AK; Dickson EJ; Imrie CW; Carter R; McKay CJ; McMillan DC
Ann Surg Oncol; 2011 Aug; 18(8):2318-28. PubMed ID: 21267785
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma in the Netherlands: A Nationwide Retrospective Analysis.
de Rooij T; Tol JA; van Eijck CH; Boerma D; Bonsing BA; Bosscha K; van Dam RM; Dijkgraaf MG; Gerhards MF; van Goor H; van der Harst E; de Hingh IH; Kazemier G; Klaase JM; Molenaar IQ; Patijn GA; van Santvoort HC; Scheepers JJ; van der Schelling GP; Sieders E; Busch OR; Besselink MG;
Ann Surg Oncol; 2016 Feb; 23(2):585-91. PubMed ID: 26508153
[TBL] [Abstract][Full Text] [Related]
18. Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma.
Maire F; Hammel P; Terris B; Paye F; Scoazec JY; Cellier C; Barthet M; O'Toole D; Rufat P; Partensky C; Cuillerier E; Lévy P; Belghiti J; Ruszniewski P
Gut; 2002 Nov; 51(5):717-22. PubMed ID: 12377813
[TBL] [Abstract][Full Text] [Related]
19. Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center retrospective study.
Matsumoto I; Murakami Y; Shinzeki M; Asari S; Goto T; Tani M; Motoi F; Uemura K; Sho M; Satoi S; Honda G; Yamaue H; Unno M; Akahori T; Kwon AH; Kurata M; Ajiki T; Fukumoto T; Ku Y
Pancreatology; 2015; 15(6):674-80. PubMed ID: 26467797
[TBL] [Abstract][Full Text] [Related]
20. Clinical impacts of resection margin status and clinicopathologic parameters on pancreatic ductal adenocarcinoma.
Jamiyan T; Shiraki T; Kurata Y; Ichinose M; Kubota K; Imai Y
World J Surg Oncol; 2020 Jun; 18(1):137. PubMed ID: 32571348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
